David Peereboom
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence (NCT04013672) | David Peereboom | 2020-03-19 |
| Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM (NCT03452579) | David Peereboom | 2018-05-21 |
Track David Peereboom automatically
Every clearance here is in the API, with alerts when new ones post.